Brief: Apogee Announces First Participants Dosed in Phase 1 Trial of APG808 for Chronic Obstructive Pulmonary Disease (COPD)
25/03/2024 13:17
March 25 (Reuters) - Apogee Therapeutics Inc APGE.O :
* APOGEE THERAPEUTICS INC - HAS INITIATED DOSING OF HEALTHY
VOLUNTEERS IN ITS FIRST CLINICAL TRIAL FOR APG808
* APOGEE THERAPEUTICS INC - INTERIM SUBCUTANEOUS SAFETY AND
PHARMACOKINETIC DATA FROM HEALTHY VOLUNTEERS ANTICIPATED IN 2H
2024
Source text for Eikon: ID:nGNXnKWm0
Further company coverage: APGE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Apogee Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Abbvie Seeks At Least $8 Billion In Debt To Fund Apogee Deal - Bloomberg News
Street View: Strength in AbbVie's immunology pipeline to support revenue growth
AbbVie trims 2026 profit view on Apogee deal, tops second-quarter estimates (updated)